Skip to main content
$5.03 $0.05 (1.0%)

04:00 PM EDT on 10/26/21

Adaptimmune Therapeutics plc (NASDAQ:ADAP)

CAPS Rating: 2 out of 5

Current Price $5.03 Mkt Cap $777.3M
Open $5.00 P/E Ratio 0.00
Prev. Close $5.03 Div. (Yield) $0.00 (0.0%)
Daily Range $4.93 - $5.10 Volume 383,918
52-Wk Range $3.37 - $7.34 Avg. Daily Vol. 2,557,654

Caps

How do you think NASDAQ:ADAP will perform against the market?

Add Stock to CAPS Watchlist

All Players

34 Outperform
4 Underperform
 

All-Star Players

13 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ADAP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.00)
Submitted May 14, 2015

Adaptimmune is another addition for zzporte's basket of CAR-T/affinity-enhanced TCR immunotherapy stocks that already includes Juno, Kite, and Bellicum in the US and others in Europe. I don't think we have any enormous insight into this recent IPO,… More

SmartAce (98.05)
Submitted January 15, 2020

My wife gets mad if we put the milk back in the fridge with only one sip left which is weird based on all her 96% empty shampoo bottles.

NASDAQ:ADAP VS S&P 500 (SPY)

NASDAQ:ADAP Summary

Fools bullish on NASDAQ:ADAP are also bullish on:

Fools bearish on NASDAQ:ADAP are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ADAP.

Recs

0
Member Avatar Hendrickson71 (< 20) Submitted: 10/21/2015 4:29:46 PM : Outperform Start Price: $9.00 NASDAQ:ADAP Score: -168.77

Different from the other T-CARs next year expanding away from oncology into other areas.....this is no one trick pony.

Recs

0
Member Avatar StockMarketKid13 (48.19) Submitted: 6/21/2015 8:22:23 PM : Outperform Start Price: $19.27 NASDAQ:ADAP Score: -192.46

good

Recs

3
Member Avatar zzlangerhans (99.00) Submitted: 5/14/2015 6:56:39 AM : Outperform Start Price: $16.50 NASDAQ:ADAP Score: -189.23

Adaptimmune is another addition for zzporte's basket of CAR-T/affinity-enhanced TCR immunotherapy stocks that already includes Juno, Kite, and Bellicum in the US and others in Europe. I don't think we have any enormous insight into this recent IPO, but I do like the fact that they are already in clinical trials and the lead candidate is partnered with GSK. Our 400 shares at 19.01 value the company at over a billion, but of course if the technology works that will seem relatively low. Success from one of the more advanced companies like Juno may also exert a bootstrap effect on the earlier stage outfits.

Leaderboard

Find the members with the highest scoring picks in ADAP.

Score Leader

svenof

svenof (49.42) Score: +162.98

The Score Leader is the player with the highest score across all their picks in ADAP.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
svenof 49.42 12/1/2015 Underperform 5Y $9.26 -45.68% +117.30% +162.98 0 Comment
capstrarian 82.08 1/29/2019 Underperform 5Y $4.67 +7.71% +73.06% +65.35 0 Comment
sln 37.88 4/5/2021 Underperform 5Y $5.63 -10.66% +13.02% +23.68 0 Comment
BigCaps18 31.71 12/23/2020 Underperform 5Y $4.95 +1.62% +23.82% +22.21 0 Comment
TMFGBudwell 64.90 3/10/2020 Outperform 5Y $3.04 +65.73% +62.38% +3.35 0 Comment
shonny2 52.24 12/18/2020 Outperform 5Y $4.51 +11.53% +22.92% -11.39 0 Comment
foggs1 67.36 3/17/2021 Outperform 5Y $5.20 -3.27% +15.58% -18.85 0 Comment
quinpeung 55.15 11/13/2020 Outperform 5Y $4.80 +4.79% +28.36% -23.56 0 Comment
staebsstreet 48.81 1/26/2021 Outperform 5Y $5.54 -9.21% +18.69% -27.89 0 Comment
odocoileus 58.66 11/9/2020 Outperform 5Y $5.16 -2.52% +26.72% -29.24 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ADAP.